The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE
Abstract
Cancer is an increasingly recognized problem associated with immunosuppression. Recent reports, however, suggest that the immunosuppressive agent rapamycin has anti-cancer properties that could address this problem. Thus far, rapamycin's effects on immunity and cancer have been studied separately. Here we tested the effects of rapamycin, versus cyclosporine A (CsA), on established tumors in mice simultaneously bearing a heart allograft. In one tumor-transplant model, BALB/c mice received subcutaneous syngenic CT26 colon adenocarcinoma cells 7 days before C3H ear-heart transplantation. Rapamycin or CsA treatment was initiated with transplantation. In a second model system, a B16 melanoma was established in C57BL/6 mice that received a primary vascularized C3H heart allograft. In vitro angiogenic effects of rapamycin and CsA were tested in an aortic ring assay. Results show that CT26 tumors grew for 2 weeks before tumor complications occurred. However, rapamycin protected allografts, inhibited tumor growth, and permitted animal survival. In contrast, CsA-treated mice succumbed to advancing tumors, albeit with a functioning allograft. Rapamycin's antitumor effect also functioned in severe combined immunodeficient BALB/c mice. Similar effects of the drugs occurred with B16 melanomas and primary vascularized C3H allografts in C57BL/6 mice. Furthermore, in this model, rapamycin inhibited the tumor growth-enhancing effects of CsA. Moreover, in vitro experiments showed that CsA promotes angiogenesis by a transforming growth factor-beta-related mechanism, and that this effect is abrogated by rapamycin. This study demonstrates that rapamycin simultaneously protects allografts from rejection and attacks tumors in a complex transplant-tumor situation. Notably, CsA protects allografts from rejection, but cancer progression is promoted in transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice
Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., & Akhurst, R. J. (1995) · Development · doi:10.1242/dev.121.6.1845 · Cited by 1,029
Recurrence of bronchioloalveolar carcinoma in transplanted lungs
Garver, R. I., Zorn, G. L., Wu, X., McGiffin, D. C., Young, K. R., & Pinkard, N. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904083401403 · Cited by 102
Cited by
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Immunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 621
Malignancy after Transplantation
Buell, J. F., Gross, T. G., & Woodle, E. S. (2005) · Transplantation · doi:10.1097/01.tp.0000186382.81130.ba · Cited by 595
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204166 · Cited by 593
Metadata
- Authors
- Koehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., & Geissler, E. K.
- Venue
- Transplantation
- Published
- 2004-05
- Volume
- 77
- Issue
- 9
- Pages
- 1319-1326
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2059257410
- Cited by
- 222
- References
- 2
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE. https://app.cochat.ai/papers/10.1097/00007890-200405150-00002
- The paper
- Koehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., & Geissler, E. K. (2004). RAPAMYCIN PROTECTS ALLOGRAFTS FROM REJECTION WHILE SIMULTANEOUSLY ATTACKING TUMORS IN IMMUNOSUPPRESSED MICE. Transplantation. https://doi.org/10.1097/00007890-200405150-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.